The specific mechanism(s) by which TYSABRI exerts its effects in relapsing MS have not been fully defined.1
In demyelinating diseases such as MS, evidence suggests α4-integrin may play a key role in inhibiting CNS migration of lymphocytes—a trigger in the inflammatory process in MS. TYSABRI is a monoclonal antibody that may help control inflammatory activity in MS through inhibition of α4-integrin.1,3
CNS=central nervous system.
TYSABRI is a 1-hour IV infusion administered once every 28 days.1
Remember: Only orders from infusion centers and certified pharmacies enrolled in and authorized by the TOUCH® Prescribing Program will be processed. Contact Biogen at 1-800-456-2255.
In the AFFIRM trial, a 2-year, multicenter, double-blind, placebo-controlled study in 942 patients with relapsing MS, TYSABRI significantly reduced1,2:
AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS; Gd+=gadolinium-enhancing; EDSS=Expanded Disability Status Scale.
aDefined as an increase of ≥1.0 point on the EDSS from baseline EDSS ≥1.0 that was sustained for 12 weeks, or a ≥1.5-point increase on the EDSS from a baseline EDSS of 0 that was sustained for 12 weeks.1
PML=progressive multifocal leukoencephalopathy; REMS=Risk Evaluation and Mitigation Strategy.
bInfusion reactions were defined as any event that occurred within 2 hours after the start of the infusion.
cPercentage based on female patients only.
PML=progressive multifocal leukoencephalopathy.
The Above MS™ program from Biogen gives patients access to Support Coordinators who can help them understand their insurance coverage and try to identify the best financial assistance solution for them. Our goal is that no one has to forgo treatment based solely on financial limitations.
Financial and insurance services include a $0 Copay Program with no income requirements and no enrollment time limit for eligible patients.d
To learn more about the financial services offered, patients can call one of our Support Coordinators at 1-800-456-2255, Monday through Friday, 8:30 AM to 8:00 PM ET.
dDepending on patients’ income or, in some cases, if their medication is obtained from an out-of-network provider, there may be an annual cap that limits the amount of assistance that they can receive over one year. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll.
Biogen, the company behind TYSABRI, has spent more than 20 years developing treatments for people with relapsing MS. For the most information, your patients can visit our patient-friendly website—TYSABRI.com.
Remind your patients that Biogen Support Coordinators are available to assist with any questions or concerns. Patients can call 1-800-456-2255, Monday through Friday from 8:30 AM to 8:00 PM ET.
AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS.